Chemotherapeutic resistance: surviving stressful situations.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21771909.
- Also identified by DOI 10.1158/0008-5472.CAN-11-0277 and PMC identifier 3148403.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chemotherapeutic regimens involve the systemic administration of genotoxic compounds that induce cancer cell death via well-established DNA damage response signaling networks. Less understood is how the treatment of other cell types within the tumor microenvironment affects the therapeutic response. Here we discuss recent work that shows that tumor-adjacent cells can respond to genotoxic stress by activating a paracrine secretory program. Although this secretory response serves to protect progenitor cells and promote tissue regeneration in conditions of cellular stress, it can also be coopted by tumor cells to survive frontline chemotherapy. Thus, local prosurvival signaling may present a fundamental barrier to tumor clearance by genotoxic agents, suggesting that effective treatments need to target both cancer cells and the tumor microenvironment.
Medical subject headings
- Antineoplastic Agents
- DNA Damage
- Drug Resistance, Neoplasm
- Paracrine Communication
- Stromal Cells
- Tumor Microenvironment